Two biotechs go for pub­lic of­fer­ings; Pfiz­er part­ner ex­pands on­col­o­gy col­lab

Af­ter the FDA ap­proved Re­vance’s Daxxi­fy as a longer-last­ing al­ter­na­tive to Ab­b­Vie’s cash cow Botox, Re­vance is look­ing to top off its cof­fers.

The aes­thet­ics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER